Biotricity (US:BTCY) ZACKSยท2025-11-14 23:01Financial Performance - Biotricity Inc. reported a quarterly loss of $0.03 per share, better than the Zacks Consensus Estimate of a loss of $0.08, and an improvement from a loss of $0.07 per share a year ago, representing an earnings surprise of +62.50% [1] - The company posted revenues of $3.89 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.36%, but showing an increase from $3.27 million in the same quarter last year [2] Stock Performance - Biotricity shares have increased approximately 82.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 14.6% [3] - The current Zacks Rank for Biotricity is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $4.1 million, and for the current fiscal year, it is -$0.32 on revenues of $15.8 million [7] - The estimate revisions trend for Biotricity was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - Biotricity operates within the Zacks Medical Info Systems industry, which is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]